Contributing Member of the Healthcare Councils
Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.
GLG News by this Author
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
Government Intervention is Here: Pharma had better get use to it....
October 6, 2008
Roche Cuts Price of Cancer Drug | online.wsj.com
"U.K. Health Service Agrees to Pay for Tarceva Following the Company's Discount" so that the price is equivalent to Taxotere.
-
Radon & Lung cancer: Outside of Uranium Mines is it Relevant???
October 3, 2008
Protecting a Home From Silent Threat | www.nytimes.com
Radon is responsible for about 15% on lung cancer deaths in the US??
-
Idera Pharma: is there room for another agent in recurrent renal cell ca??
October 2, 2008
Idera Pharmaceuticals Announces Preliminary Data from Phase 2a Clinical Study of IMO-2055 Monotherapy in Renal Cell Carcinoma | www.pipelinereview.com
Apparently Merck has an interest in this compound and it is in trial in combination in other neoplasms.
-
Epo & Stroke: The chickens coming home to roost.
September 30, 2008
F.D.A. Reviewing Deaths in Anemia Drug Study | www.nytimes.com
Epo (J & J's version) increased mortality when given to patients with a new stroke in an effort to improve brain function. What will this lead too??
-
Oh, Good, Not only won't seniors be able to understand it; they won't be able to afford it?
September 29, 2008
Medicare Drug Premium on Rise | online.wsj.com
Costs for Medicare part D are going up 31%
-
Molecular profiles in lung cancer: THE FUTURE IS HERE....
September 26, 2008
Lung Cancer | content.nejm.org
Clinical trials are being built around determining which molecular profiles require what therapy. It's here!!
-
Lilly to Disclose Payments to Doctors: What a revolting development this is!
September 24, 2008
Lilly to Disclose Payments to Doctors | online.wsj.com
It will become public knowledge what Doctors are paid by Lilly for advice, lectures and other services.
-
3 week radiation for breast cancer: What is the cosmetic end result?
September 23, 2008
Shorter Radiation for Cancer of the Breast | www.nytimes.com
Results are identicle (3 weeks v 5 in post lumpectomy radiation?)
-
Can physicians adapt to proposed IT requirements?
September 22, 2008
Stark Offers Bill to Hasten e-record Adoption | modernhealthcare.com
Adoption of mandatory computerization will be gently forced on physicians and their offices
-
I know, I know there is no money in diagnostics but....
September 19, 2008
Raising the Profile of Cancer of Unknown Primary | jco.ascopubs.org
RNA gene profiling will allow up to get a better handle on the primary site, especially with increasing targeting opportunities in many neoplasms.
-
"Star Wars" technology interfaces with radiation oncology
September 18, 2008
Proton Radiotherapy: A Review | www.nytimes.com
Proton beam therapy will effect the market place and force competition for oncology centers to get "the next best thing."
-
Velcade 1st line? No surprise.....
September 9, 2008
Velcade (Black Triangle Drug) (bortezomib) Approved For Previously Untreated Multiple Myeloma | www.therapeuticsdaily.com
Velcade, given with Melphalan & Prednisone approved for use 1st line in non-transplant myeloma patients first line.
-
IT'S ALIVE!!?? Astra Zeneca's (AZ) Iressa (At least in Japan)
September 9, 2008
Gefitinib Versus Vinorelbine in Chemotherapy-Naïve Elderly Patients With Advanced Non–Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study | jco.ascopubs.org
2 separate studies show that: 1. "...there was no statistically significant difference in overall survival....for gefitinib compared with docetaxel. Gefitinib remains an effective treatment option for previously treated Japanese patients with NSCLC." http://jco.ascopubs.org/cgi/content/full/26/26/4244 2. There was no statistical difference between gefitinib and vinorelbine in efficacy in chemotherapy-naïve, unselected elderly patients with advanced NSCLC,
-
Think about the future and what this will lead to....
September 8, 2008
In Long-Awaited Maps of Cancer, The Breakthrough Is the Problem | online.wsj.com
Pharmacogenomics will lead to the development of targeting agents and offer true hope for the future.
-
GIST: So what else is new.....
September 2, 2008
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery | www.therapeuticsdaily.com
Novartis is looking for approval for therapy in C-KIT + Gastrointestinal stromal tumors
-
Bcl-2 apoptosis inhibition: The next "best" thing?
August 29, 2008
Expanding Circle of Inhibition: Small-Molecule Inhibitors of Bcl-2 as Anticancer Cell and Antiangiogenic Agents | jco.ascopubs.org
Bcl-2 inhibition by small molecules stands to be the next avenue for antineoplastic therapy- Looks like the real deal!
-
August 29, 2008
Cell Genesys Ends Clinical Trials For Prostate Cancer Treatment | online.wsj.com
No reason for the increased mortality vs Chemo alone was identified. Cell Genesys is looking into where to go now.
-
Velcade in myeloma 1st line. Am I s?urprised
August 29, 2008
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma | content.nejm.org
Velcade + classic Melphalan/ Prednisone (MP) is better than MP alone. No surprise
-
Amgen's long awaited product to treat chronic ITP will be well receive.
August 25, 2008
Amgen Blood-Disorder Drug Gains Clearance | online.wsj.com
Chronic ITP is not all that uncommon and becomes a quality of life issue with chronic steroid use as well as agents that are normaly used in neoplasia and even derivatives of male hormones.
-
Artificial red blood cells (RBC'S): preliminary but very promising.
August 21, 2008
Scientists Find Way to Create Red Blood Cells | online.wsj.com
Advanced Cell Technology in Worcester, Mass., the University of Illinois at Chicago and the Mayo Clinic in Rochester, Minn. scientists say they've found an efficient way to make red blood cells from human embryonic stem cells. Impreesive!
- Subscribe to Updates
-
This author consults with leading institutions through GLG
Most Popular Healthcare News
-
February 7, 2012
-
What do the cloud, collaboration and virtualization have in common?
January 27, 2012
-
Clinical diagnostic acquisitions dominate 2011 top ten list
January 12, 2012
-
Gene therapy success threatens drugs for hemophilia and rare diseases
December 13, 2011
-
Medtech M&A activity accelerates in 2011
November 30, 2011
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.